FDA Grants Breakthrough Therapy Designation to Allay’s Therapy for Post-Surgical Pain in Total Knee Arthroplasty

The breakthrough designation is based on Phase II clinical trial data, which demonstrated that ATX101 provides sustained pain relief for up to four weeks following total knee arthroplasty.